InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.29
(
0.43%
)
Bitcoin
57,505.38
(
-4.42%
)
Post# of 252483
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: ghmm post# 151082

Thursday, 10/25/2012 9:46:37 AM

Thursday, October 25, 2012 9:46:37 AM

Post# of 252483
UTHR is already conducting another oral remodulin trial that started enrolling a few months ago:

http://clinicaltrials.gov/ct2/show/NCT01560624?term=NCT01560624&rank=1

It has 2 primary endpoints: "Time to First Clinical Worsening event" and "Change in 6 minute walk distance", but no "fixed dose design" nor "more frequent dosing"...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up